相关实验视频

Updated: May 5, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

对MAPK激活的结直肠癌的基因可用药物标通过两样本的孟德尔随机化分析

Yuxuan Zhou¹, Yunlong Ding², Bangyue Xu³

¹Department of Gastrointestinal Surgery/Hernia Surgery, Jilin Province People's Hospital, No. 1183 Gongnong Road, Changchun, Jilin, China.

Scientific reports

|April 10, 2025

概括

这项研究确定了与结直肠癌 (CRC) 风险增加相关的四种血蛋白,为这种致命疾病提供了潜在的新诊断标记物和治疗点.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
免疫学免疫学免疫学

背景情况:

结肠直肠癌 (CRC) 是全球癌症死亡的主要原因,预计发病率将增加.
MAPK信号通路,通常由RAS瘤基因突变激活,涉及超过60%的CRC病例,并提出治疗挑战.
目前对MAPK激活的CRC的治疗选择是有限的,因为这些突变的"无药"性质.

研究的目的:

研究血蛋白水平与患MAPK激活结直肠癌的风险之间的潜在因果关系.
确定用于早期检测和治疗CRC的新型血蛋白生物标志物.
探索治疗难以向的MAPK激活CRC的新途径.

主要方法:

使用了两个样本的门德尔随机化 (MR) 方法.
集成的蛋白质定量特征位点 (pQTL) 数据与CRC的遗传关联.
分析了特定血蛋白与MAPK激活的CRC风险之间的关联.

主要成果:

确定了四种与MAPK激活CRC的风险增加显著相关的血蛋白.
这些蛋白质包括MHC I类聚相关序列B (MICB),补充C4A,补充C4B,以及介质蛋白-21 (IL-21).
这些发现表明这些蛋白质在CRC病变发生和进展中可能发挥作用.

结论:

与MHC I类聚相关的序列B (MICB),补充C4A,C4B和IL-21可以作为MAPK激活的CRC的有价值的诊断标记.
这些血蛋白代表了开发针对CRC的新型干预措施的有希望的治疗点.
需要进一步的研究来验证这些发现,并探索它们在CRC管理中的临床实用性.

更多相关视频

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

Published on: July 6, 2017

相关概念视频

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...